See more : Hengan International Group Company Limited (1044.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Appili Therapeutics Inc. (APLIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Appili Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ZIOPHARM Oncology, Inc. (ZIOP) Income Statement Analysis – Financial Results
- Peet Limited (PPC.AX) Income Statement Analysis – Financial Results
- Federal Corporation (2102.TW) Income Statement Analysis – Financial Results
- GRANDTOP YONGXING GROUP CO LTD (601033.SS) Income Statement Analysis – Financial Results
- Decarbonization Plus Acquisition Corporation II (DCRNU) Income Statement Analysis – Financial Results
Appili Therapeutics Inc. (APLIF)
About Appili Therapeutics Inc.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 827.41K | 1.39M | 1.39M | 0.00 | 199.11K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.66K | 6.27K | 0.00 | 14.84K | 0.00 | 20.71K | 17.67K | 10.51K |
| Gross Profit | 813.75K | 1.38M | 1.39M | -14.84K | 199.11K | -20.71K | -17.67K | -10.51K |
| Gross Profit Ratio | 98.35% | 99.55% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.62M | 21.46M | 10.87M | 11.49M | 4.18M | 3.93M | 4.95M | 2.52M |
| General & Administrative | 3.05M | 4.56M | 4.79M | 4.79M | 2.36M | 2.36M | 1.61M | 1.24M |
| Selling & Marketing | 0.00 | 185.84K | 711.93K | 2.32K | 942.40K | 861.45K | 735.00K | -5.37K |
| SG&A | 3.05M | 4.56M | 4.79M | 4.79M | 2.36M | 3.22M | 1.61M | 1.24M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 827.41K | 24.95M | 14.37M | 16.28M | 4.37M | 7.14M | 3.77M | 3.76M |
| Cost & Expenses | 8.88M | 24.95M | 14.37M | 16.30M | 4.37M | 7.16M | 3.77M | 3.77M |
| Interest Income | 16.81K | 33.73K | 116.95K | 116.95K | 40.17K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.55M | 69.84K | 69.84K | 12.11K | 0.00 | 208.70K | 0.00 |
| Depreciation & Amortization | 13.66K | 6.27K | 12.64K | 14.84K | 17.75K | 20.71K | 17.67K | 10.51K |
| EBITDA | -2.07M | -7.91M | -24.67M | -15.65M | -5.39M | -6.52M | -6.54M | -3.22M |
| EBITDA Ratio | -249.78% | -1,690.70% | -1,023.99% | 0.00% | -2,185.64% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.05M | -23.52M | -14.26M | -16.30M | -4.37M | -7.16M | -3.77M | -3.77M |
| Operating Income Ratio | -972.94% | -1,691.61% | -1,025.06% | 0.00% | -2,196.05% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.34M | -1.29M | -401.36K | 706.93K | 28.06K | 2.21M | 2.58M | 1.47M |
| Income Before Tax | -3.71M | -25.08M | -14.33M | -14.95M | -4.33M | -4.95M | -3.98M | -2.30M |
| Income Before Tax Ratio | -448.55% | -1,803.42% | -1,030.08% | 0.00% | -2,175.22% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.58K | 38.46K | 38.46K | -627.89K | -243.43K | -621.61K | -46.18K | -541.51K |
| Net Income | -3.78M | -25.12M | -14.33M | -14.33M | -4.33M | -4.33M | -3.98M | -1.75M |
| Net Income Ratio | -456.96% | -1,806.18% | -1,030.08% | 0.00% | -2,175.22% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.22 | -0.21 | -0.24 | -0.13 | -0.14 | -0.12 | -0.06 |
| EPS Diluted | -0.03 | -0.22 | -0.21 | -0.24 | -0.13 | -0.14 | -0.12 | -0.06 |
| Weighted Avg Shares Out | 121.27M | 113.73M | 66.73M | 59.18M | 34.33M | 30.28M | 33.54M | 30.28M |
| Weighted Avg Shares Out (Dil) | 121.27M | 113.73M | 66.73M | 59.18M | 34.33M | 30.28M | 33.54M | 30.28M |
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc....
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for...
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of...
Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on...
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct....
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentation scheduled for 3:15 pm ET on October 17, 2024 HALIFAX, Nova...
Appili Therapeutics – Press Release Correction
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special...
Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF)...
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
Your vote is important no matter how many votes you hold. Shareholders who have questions or need assistance with voting their shares should contact [email protected]
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end. Business and Acquisitions Aditxt's two acquisition targets, Evofem Biosciences, Inc....
Source: https://incomestatements.info
Category: Stock Reports